Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 5, 2001, Pages 1243-1252

  Pilepich, Miljenko V ^a   Winter, Kathryn ^b   John, Madhu J ^c   Mesic, John B ^d   Sause, William ^e   Rubin, Phillip ^f   Lawton, Colleen ^g   Machtay, Mitchell ^h   Grignon, David ⁱ  

^a Ann Arbor Regional CCOP ^*  (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Radiation Oncology Center   (United States)

^e LDS HOSPITAL   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma of the prostate; Hormonal management; Radiotherapy

Indexed keywords

CARCINOMA;

CELLS; DISEASE CONTROL; TUMORS;

RADIOTHERAPY;

ANDROGEN; FLUTAMIDE; GOSERELIN;

ARTICLE; CELL KILLING; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FOLLOW UP; HUMAN; HYPOTHESIS; INCIDENCE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; REDUCTION; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LIFE TABLES; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035424063     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01579-6     Document Type: Article

References (16)

1. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
2. Nonparametric estimation from incomplete observations
3. A class of K-sample tests for comparing the cumulative incidence of a competing risk
4. Prognostic factors in carcinoma of the prostate - Analysis of RTOG study 75-06
5. Hormonal treatment before radical prostatectomy: A 3-year follow-up
6. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in treatment of localized prostate cancer
7. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
8. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-2N0M0 prostatic carcinoma
9. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer
10. Neoadjuvant androgen ablation for localized prostatic cancer. Pathology methods, surgical end points and meta-analysis of randomized trials
11. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy
12. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy
13. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer
14. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results
15. The effect of androgen deprivation on an androgen sensitive tumor; an in vivo and in vitro study
16. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy - Report of RTOG protocol